0001104659-16-138667.txt : 20160810 0001104659-16-138667.hdr.sgml : 20160810 20160810170025 ACCESSION NUMBER: 0001104659-16-138667 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 45 CONFORMED PERIOD OF REPORT: 20160810 ITEM INFORMATION: Other Events ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20160810 DATE AS OF CHANGE: 20160810 FILER: COMPANY DATA: COMPANY CONFORMED NAME: AMICUS THERAPEUTICS INC CENTRAL INDEX KEY: 0001178879 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 200422823 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33497 FILM NUMBER: 161822139 BUSINESS ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 BUSINESS PHONE: (609) 662-2000 MAIL ADDRESS: STREET 1: 1 CEDAR BROOK DRIVE CITY: CRANBURY STATE: NJ ZIP: 08512 8-K 1 a16-16553_18k.htm 8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

WASHINGTON, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT PURSUANT TO
SECTION 13 OR 15(D) OF THE
SECURITIES EXCHANGE ACT OF 1934

 

Date of Report (Date of earliest event reported): August 10, 2016

 

AMICUS THERAPEUTICS, INC.

(Exact Name of Registrant as Specified in Its Charter)

 

Delaware

(State or Other Jurisdiction of
Incorporation)

 

001-33497

 

71-0869350

(Commission File Number)

 

(IRS Employer Identification No.)

 

1 Cedar Brook Drive, Cranbury, NJ

 

08512

(Address of Principal Executive Offices)

 

(Zip Code)

 

Registrant’s telephone number, including area code: (609) 662-2000

 

 

(Former Name or Former Address, if Changed Since Last Report.)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

 

 



 

Item 8.01.  Other Events.

 

The senior management of Amicus Therapeutics, Inc. (the “Company”) is using the presentation attached as Exhibit 99.1 to this Current Report in its current meetings with investors and analysts.

 

Item 9.01. Financial Statements and Exhibits.

 

(d) Exhibits:  The Exhibit Index annexed hereto is incorporated herein by reference.

 

2



 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

 

Amicus Therapeutics, Inc.

 

 

Date: August 10, 2016

By:

/s/ Ellen S. Rosenberg

 

 

Ellen S. Rosenberg

 

 

General Counsel and Corporate Secretary

 

3



 

EXHIBIT INDEX

 

Exhibit No.

 

Description

99.1

 

Presentation Materials

 

4


EX-99.1 2 a16-16553_1ex99d1.htm EX-99.1

Exhibit 99.1

Corporate Overview August 2016

GRAPHIC

 


Safe Harbor This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 relating to preclinical and clinical development of our product candidates, the timing and reporting of results from preclinical studies and clinical trials, the prospects and timing of the potential regulatory approval of our product candidates, commercialization plans, financing plans, and the projected cash position for the Company. The inclusion of forward-looking statements should not be regarded as a representation by us that any of our plans will be achieved. Any or all of the forward-looking statements in this press release may turn out to be wrong and can be affected by inaccurate assumptions we might make or by known or unknown risks and uncertainties. For example, with respect to statements regarding the goals, progress, timing, and outcomes of discussions with regulatory authorities, and in particular the potential goals, progress, timing, and results of preclinical studies and clinical trials, actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in our business, including, without limitation: the potential that results of clinical or preclinical studies indicate that the product candidates are unsafe or ineffective; the potential that it may be difficult to enroll patients in our clinical trials; the potential that regulatory authorities, including the FDA, EMA, and PMDA may not grant or may delay approval for our product candidates; the potential that we may not be successful in commercializing Galafold in Europe or our other product candidates if and when approved; the potential that preclinical and clinical studies could be delayed because we identify serious side effects or other safety issues; and the potential that we will need additional funding to complete all of our studies. Further, the results of earlier preclinical studies and/or clinical trials may not be predictive of future results. With respect to statements regarding projections of the Company's cash position, actual results may differ based on market factors and the Company's ability to execute its operational and budget plans. In addition, all forward-looking statements are subject to other risks detailed in our Annual Report on Form 10-K for the year ended December 31, 2015. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement, and we undertake no obligation to revise or update this news release to reflect events or circumstances after the date hereof. 2 Introduction

GRAPHIC

 


Amicus 2016 – Looking Back 3 Introduction Chaperone Technology for LSDs Small molecules U.S. rights to Galafold™ (migalastat) Callidus acquisition Biologics Global rights to migalastat Positive Phase 3 data for migalastat Biologics scale-up International HQ MAA Submission Scioderm acquisition Pompe ERT in clinic Amicus Has Greatly Expanded Product Pipeline, Technologies and Geographies 2012 2013 2014 2015

GRAPHIC

 


Amicus 2016 – Continuing the Momentum 4 Introduction Galafold EU approval for Fabry FDA regulatory clarity for Galafold EB Phase 3 data Pompe clinical data 2016 Target Milestones Chaperone Technology for LSDs Small molecules U.S. rights to Galafold Callidus acquisition Biologics Global rights to Galafold Galafold positive Phase 3 data Biologics scale-up International HQ MAA Submission Scioderm acquisition Pompe ERT in clinic Significant Milestones in 2016 2012 2013 2014 2015

GRAPHIC

 


Amicus Vision Introduction 5 Amicus Therapeutics is a global biotechnology company at the forefront of developing advanced therapies to treat a range of devastating rare and orphan diseases Potential First-in-Class / Best-in-Class Meaningful Benefits for Patients Rare & Devastating Diseases

GRAPHIC

 


Key Drivers of Value Introduction 6 3 Novel Product Candidates Each with $500M to $1B+ Market Potential Galafold Precision Medicine (Small Molecule) EU Full Approval Launched in Germany (May 30, 2016) U.S. regulatory update anticipated 3Q16 Phase 3 Novel Topical Cream (SD-101) U.S. Breakthrough Therapy Designation Rolling NDA Phase 3 Data targeted in 4Q16/1H17 Novel ERT + Chaperone Treatment Paradigm Biologics Manufacturing Interim Data Anticipated in 4Q16 R&D Engine and Continued Business Development Activity Pompe Epidermolysis Bullosa (EB) Fabry

GRAPHIC

 


Galafold™ (Migalastat) Precision Medicine for Fabry Disease

GRAPHIC

 


European Commission Granted Full Approval for Galafold Galafold: Precision Medicine for Fabry Disease 8 Galafold Indicated for Long-Term Treatment of Adults and Adolescents Aged > 16 years with a Confirmed Diagnosis of Fabry Disease and Who have an Amenable Mutation The evaluation of EMA’s Committee for Medicinal Products for Human Use (CHMP) was based on the results of two phase III clinical trials in about 110 patients with Fabry disease who had a genetic mutation which responds to migalastat. Galafold demonstrated its efficacy compared to placebo (a dummy treatment) and to ERT in a long-term comparative study. - EMA Press Release Hard Capsules Oral Use 14 Hard Capsules

GRAPHIC

 


Fabry Disease Overview Galafold: Precision Medicine for Fabry Disease 9 Fabry Disease is a Fatal Genetic Disorder that Affects Multiple Organ Systems Leading Causes of Death Life-Limiting Symptoms TRANSIENT ISCHEMIC ATTACK (TIA) & STROKE1 KIDNEY DISEASE3 Protein in the urine Decreased kidney function Kidney failure HEART DISEASE2 Irregular heartbeat (fast or slow) Heart attack or heart failure Enlarged heart GASTROINTESTINAL3 Nausea, vomiting, cramping, and diarrhea Pain/bloating after eating, feeling full Constipation Difficulty managing weight Deficiency of α-Gal A enzyme leading to GL-3 accumulation >800 known mutations 5-10K diagnosed WW (51% female/49% male4) Newborn screening studies suggest prevalence of ~1:1000 to ~1:4000 Key Facts 1. Desnick R, et al. Ann Intern Med. 2003 2. Yousef Z, et al. Eur Heart J. 2013 3. Germain D. Orphanet J Rare Dis. 2010 4. Fabry Registry 2011

GRAPHIC

 


Summary of Clinical Data Galafold: Precision Medicine for Fabry Disease 10 Favorable Efficacy and Safety Data in Two Largest Phase 3 Studies Ever Completed in Fabry Disease 1: Improvement versus placebo over 6 months in amenable patients 2: Improvement from baseline over 18+ months 3: Comparable to ERT over 18 months 4: Stabilization from baseline over 18 months with favorable comparison to natural history in literature Reduction in Cardiac Mass Left Ventricular Mass Index (LVMI) (Study 0112 and 012)* Improvement in GI Symptoms Gastrointestinal Symptoms Rating Scale (GSRS) (Study 0111)* Reduction in Disease Substrate IC GL-3 (Study 0111)* Plasma Lyso Gb-3 (Study 0112,1 and 0123)* Low Rate of Fabry-Associated Clinical Events Renal, Cardiac and Cerebro-Vascular Events (Study 0123) Stability of Kidney Function Estimated Glomerular Filtration Rate (eGFR) and Measured GFR (Study 0114 and Study 0124,3) *Analyses in this endpoint achieved statistical significance. For more complete clinical data go to amicusrx.com/posters.aspx

GRAPHIC

 


Galafold Commercial Opportunity Galafold: Precision Medicine for Fabry Disease 11 Amicus is Prioritizing EU, Japan, US and Other Large Fabry Markets for Initial Launch Go To Market Strategy to Address 35%-50% of Patients with Amenable Mutations 1. Company filings and Amicus estimates 5k-10k Diagnosed WW (40-50% of Diagnosed Patients Not on ERT Today) Market Continues to Grow > 10% / Year U.S. 27% EU 34% ROW 26% $1.2B in FY15 ERT Sales1 Market Continues to Grow > 10% / Year ERT Infused Once Every 2 Weeks Japan 13% ERT-Treated Diagnosed Untreated Undiagnosed 5k-10k Patients Diagnosed WW 40%-50% of Diagnosed Patients not on ERT Newborn screening studies suggest prevalence of ~1:1000 to ~1:4002 amenable mutations = Geographic Segments Patient Segments 2. Burton, LDN WORLD Symposium, 2012 Feb. Mechtler et al., The Lancet, 2011 Dec. Hwu et al., Hum Mutation, 2009 Jun. Spada et al., Am J Human Genet., 2006 Jul

GRAPHIC

 


International Launch Update Galafold: Precision Medicine for Fabry Disease 12 EU Market Represents 34% of FY15 ERT Global Sales ($1.2B) UNITED KINGDOM ERT-treated patients: ~450 Highly Specialised Technology (HST) FRANCE ERT-treated patients : ~375 patients Multiple patients treated under ATU GERMANY ERT-treated patients : ~500 patients ~50% of diagnosed patients untreated Galafold launched – initial patients on treatment

GRAPHIC

 


EU Launch Update Galafold: Precision Medicine for Fabry Disease 13 Successful Early Days of EU Launch with Naïve and Switch Patients on Galafold – Focusing on Patient Access and Country-by-Country Reimbursement Processes LAUNCH IN GERMANY = IMPORTANT INDICATOR First Galafold Rx within 24 hours of EC approval Patient support program Experienced, high quality team Pricing dossier submitted patients (switch & naïve) on reimbursed Galafold WW (7/31/16)) 21 countries with reimbursement (commercial and EAP) 3 countries with active pricing discussions 12

GRAPHIC

 


Global Regulatory Strategy Galafold: Precision Medicine for Fabry Disease 14 EU Approval and Launch (May 30, 2016) Expanded Access Programs (EAP) in 2 Territories with More Coming Online Prioritizing Global Regulatory Submissions in Key Markets (US and Japan) with Additional Submissions Completed or Planned Based on EU Approval (MAA) 4 Additional Regulatory Submissions Complete, Process Initiated in Other Key Geographies FDA Update Anticipated in 3Q16 Japanese NDA Submission Anticipated 1H17

GRAPHIC

 


Amicus Proprietary Fabry ERT Target Fabry ERT product profile: Improved drug targeting Co-formulation with chaperone Novel Proprietary Fabry ERT 15 Building on Biologics Capabilities and CHART Platform to Develop Differentiated Novel ERT Development status: Cell line transferred to manufacturer Preclinical data update in 2H16

GRAPHIC

 


CHART Preclinical Proof-of-Concept for Fabry Co-Formulation Novel Proprietary Fabry ERT 16 Co-Formulation (ERT + Migalastat) Results in Significantly Greater Tissue Uptake and Further Substrate Reduction* Heart GL-3 *ERT designed to be biosimilar to Fabrazyme; **0 = wild-type, 100 = untreated KO mouse % Elevated > Wild-Type** % Elevated > Wild-Type** Kidney GL-3 A-Gal A Tissue Uptake GL-3 Substrate Reduction *ERT+/- Migalastat HCl in GLA Knock-Out Mice (Repeat-Dose IV Administration) JR-051 (1 mg/kg ) JR-051 (3 mg/kg) JR-051 (1 mg/kg ) JR-051 (3 mg/kg) Heart Kidney 4 3 2 0.8 0.6 0.4 0.2 0 α-Gal A (nmol/mg protein/hr) JR-051 (1 mg/kg ) JR-051 (3 mg/kg ) JR051 alone JR051 + migalastat 2.5 2.0 1.5 1.0 0.5 0 α-Gal A (nmol/mg protein/hr) JR-051 (1 mg/kg ) JR-051 (3 mg/kg ) JR051 alone JR051 + migalastat 0 20 40 60 80 0 20 40 60 80

GRAPHIC

 


Fabrazyme 1 mg/kg Fabrazyme 0.5 mg/kg Replagal 0.2 mg/kg CHART Phase 2a Results for Fabry Co-Administration Study 013 Novel Proprietary Fabry ERT 17 Co-Administration with Fabrazyme or Replagal Leads to Consistent Increases in Active Plasma Enzyme Levels and Tissue Uptake1 1 Bichet, et al., A Phase 2a Study to Investigate the Effect of a Single Dose of Migalastat HCl, a Pharmacological Chaperone, on Agalsidase Activity in Subjects with Fabry Disease, LDN WORLD 2013. Plasma rhGLA Activity (Area Under Curve) Plasma AUC rhGLA Activity (hr*nmol/hr/mL) Mean Skin GLA Activity (Day 2) Mean Skin GLA Activity (pmol/mg/hr) Replagal 0.2 mg/kg (n=4) Fabrazyme 0.5 mg/kg (n=1) Fabrazyme 1 mg/kg (n=6) 0 1,000 2,000 3,000 4,000 5,000 ERT Alone ERT + migalastat 450 mg +127% +267% +77% 0 5,000 10,000 15,000 20,000 ERT Alone ERT + 450 mg Migalastat +179% +144% +125%

GRAPHIC

 


Fabry Franchise Strategy Fabry Franchise 18 Amicus Therapeutics is Committed to Delivering the Highest Quality Therapies and Future Innovation to Find a Cure for ALL Fabry Patients ERTs ERTs Galafold Amicus ERT (ERT+Chaperone) Galafold Future Innovative Therapies Yesterday Today Tomorrow

GRAPHIC

 


ATB200 Novel ERT for Pompe Disease A Proprietary, Clinical-Stage Biologics Program

GRAPHIC

 


Pompe Disease Overview Novel ERT for Pompe Disease – ATB200 + Chaperone 20 Severe, Fatal, Genetic Disorder with Significant Unmet Medical Need Deficiency of GAA leading to glycogen accumulation Age of onset ranges from infancy to adulthood Symptoms include muscle weakness, respiratory failure, and cardiomyopathy Respiratory and cardiac failure are leading causes of morbidity and mortality 5,000 – 10,000 patients diagnosed WW1 ~$800M+ Global Pompe ERT sales in FY152 1. National Institute of Neurological Disorders and Stroke (NIH). 2. Sanofi Press Release & 10-K

GRAPHIC

 


Pompe ERT - 3 Challenges Novel ERT for Pompe Disease – ATB200 + Chaperone 21 Activity/ Stability Rapid denaturation of ERT in pH of blood1 Tolerability / Immunogenicity Infusion-associated reactions in >50% of late-onset patients3 Uptake/ Targeting Low M6P receptor uptake into skeletal muscle2 Antibody titers shown to affect treatment outcomes4,5 Vast majority of rhGAA not delivered to lysosomes2 Protein Aggregation 1Khanna et al., PLoS ONE, 2012; 2Zhu et al., Amer. Soc. Gene Therapy, 2009 June; 3Banati et al., Muscle Nerve, 2011 Dec.; 4Banugaria et al., Gen. Med., 2011 Aug.; 5de Vries et al., Mol Genet Metab., 2010 Dec. Amicus Technology Platforms with Potential to Address Challenges with Existing Pompe ERT Uniquely Engineered rhGAA Optimized M6P & Carbohydrates

GRAPHIC

 


Preclinical Proof of Concept Novel ERT for Pompe Disease – ATB200 + Chaperone 22 ATB200 + Chaperone Results in Improved Substrate Clearance in Preclinical Models1 Untreated Alglucosidase Alfa ATB200 + AT2221 Wild-Type PAS (20x) Untreated Alglucosidase Alfa ATB200 +AT2221 Wild-Type LAMP1 (40x) 1. Following 2 doses of 20mg/kg alglucosidase alfa or ATB200 + AT2221 in Gaa KO mice, skeletal muscles evaluated for glycogen clearance and proliferated lysosomes. Treatment with alglucosidase alfa modestly reduced glycogen or proliferated lysosomes while ATB200, co-administered with AT2221 significantly decreased the muscle pathology associated with Pompe disease. PAS-glycogen staining in Quadriceps LAMP1 Immunohistochemical staining in Soleus

GRAPHIC

 


Human Proof-of-Concept: Currently Marketed ERT + Chaperones Novel ERT for Pompe Disease – ATB200 + Chaperone 23 ERT Activity Increased and Infusion Time Decreased with ERT + Chaperone 1 Kishnani, et al., LDN WORLD 2013 2 Doerfler, et al. WORLD 2014 * Cohort 1 (AT2220 50 mg) muscle GAA activity not shown; 50 mg dose did not demonstrate meaningful change in tissue uptake (muscle) Plasma AUC GAA Activity (hr*nmol/hr/mL) Time of Enrollment (Months) Infusion Duration (Hours) Patient 1 Patient 2 8 4 0 12 8 4 2 0 6 Amicus Phase 2 Study 010 Enzyme Activity1 Investigator-Initiated Study Infusion Time2 0 50,000 100,000 150,000 200,000 250,000 300,000 ERT Alone ERT + AT2220 Cohort 1 (n=4) Cohort 2 (n=6) Cohort 3 (n=6) Cohort 4 (n=7) +110% (Cohort 4) +70% (Cohort 2) +100% (Cohort 3) +50% (Cohort 1)

GRAPHIC

 


Biologics Manufacturing Capabilities Novel ERT for Pompe Disease – ATB200 + Chaperone 24 Optimized Glycosylation and Key Quality Attributes Maintained Through Scale Up rhGAA lacks M6P; cannot be targeted to lysosomes rhGAA contains M6P; targeted to lysosomes Lyophilized Vial of ATB200 GAA Activity (nmol/mL/hr) GAA Activity (nmol/mL/hr) GAA Activity (nmol/mL/hr) M6P [mM] M6P [mM] M6P [mM] CI-MPR Receptor Chromatography GAA Activity M6P Bench Scale 5L Scale 250L Scale Proof of Concept Studies 0 20 40 60 80 0 1 2 3 4 5 8% 92% G A A A c t i v i t y ( n m o l / m L / h r ) M 6 P [ m M ] 0 15 30 45 60 0 1 2 3 4 5 5L Bioreactor Run G A A A c t i v i t y ( n m o l / m L / h r ) M 6 P [ m M ] GAA Activity M6P (mM) 11% 89% 0 20 40 60 80 0 1 2 3 4 5 Engineering Run 2 G A A A c t i v i t y ( n m o l / m L / h r ) M 6 P [ m M ] 9% 91%

GRAPHIC

 


Clinical Study in Pompe Patients Novel ERT for Pompe Disease – ATB200 + Chaperone 25 Stage 2 (Multiple Ascending Dose) ATB200 20mg/kg + AT2221 (Low Dose) ATB200 20mg/kg + AT2221 (High Dose) ATB200 5 mg/kg Stage 1 (Single Ascending Dose) Single Dose ATB200 Every Other Week Fixed Dose ATB200 + Chaperone (AT2221) Every Other Week Long-Term Open-Label Extension Fixed Dose ATB200 + Chaperone (AT2221) Every Other Week Assessments: Plasma PK (Enzyme Activity & Total protein) Safety/Tolerability Antibodies Infusion-Associated Reactions Pharmacodynamics Efficacy (Long-Term Extension) ATB200 20 mg/kg ATB200 10 mg/kg Patient Dosing Underway and Enrollment Ongoing at Multiple Sites Week 2 Week 4 Week 6 Weeks 14, 16, 18 Weeks 8, 10, 12

GRAPHIC

 


Pompe Clinical Study ATB200-02 Data Cascade Novel ERT for Pompe Disease – ATB200 + Chaperone 26 Data in initial ambulatory ERT-switch patients (N=~4,Cohort 1) Data in ERT-naïve patients (Cohort 2) Additional extension study data (all Cohorts) A Cascade of Data Points from 4Q16 through 2017 Offer Clear Parameters to Define Success and Differentiate ATB200/AT2221 Pompe Data Cascade 4Q16 Through 2017 Additional data & initial extension data in Cohort 1 Data in non-ambulatory ERT-switch patients (Cohort 3) 18-WEEK DATA Safety / tolerability Pharmacokinetics (PK) Biomarkers Immunogenicity EXTENSION DATA Motor/pulmonary function

GRAPHIC

 


SD-101 for Epidermolysis Bullosa (EB) Poised to deliver pivotal data for a devastating rare disease

GRAPHIC

 


EB Disease Overview SD-101 for EB 28 Rare, Devastating, Connective Tissue Disorder with No Approved Treatments Multiple genes cause disease which results in fragility of skin and can affect internal organs Diagnosed from infancy to adulthood Severe blistering, open wounds, and scarring in response to minor friction to the skin Disfiguring, excruciatingly painful, and can be fatal Given the lack of approved treatment options, any reduction in disease symptoms would be considered meaningful 30,000 – 40,000 diagnosed patients in major global regions

GRAPHIC

 


Three Major EB Types Represent ~99% of EB Population SD-101 for EB 29 No Approved Therapies Today SD-101 in Development for All 3 Major Types 30,000 - 40,000 Diagnosed in Major Markets INCREASING SEVERITY Multiple Types Single Devastating and Fatal Genetic Disorder Simplex Dystrophic Junctional ~75% of EB Population ~20% of EB Population ~5% of EB Population

GRAPHIC

 


U.S. Breakthrough Therapy Designation Open-label, 8-patient proof of concept study1 Ages 6 months – 9 years All baseline target wounds > 10 cm2 SD-101 3% applied once daily for 3 months SD-101 for EB 30 Positive Early Results from Phase 2a Study Led to Breakthrough Therapy Designation 1. Simplex (n=3), Junctional (n=3), Dystrophic (n=2) Key Findings 1-Year-Old Girl with EB Simplex Baseline Following 2 months of treatment 87.5% of patients experienced complete closure of target wounds within 1 month Daily administration generally safe and well-tolerated 57% reduction in affected body surface area by month 3

GRAPHIC

 


Phase 2b Design (Study 003) SD-101 for EB 31 Placebo (n=17) SD-101 6% (n=15) Open-Label SD-101 6% 3-Month, Double-Blind Treatment Period1 Primary Efficacy Endpoint: Target Wound Healing at Month 1 Baseline wound: Chronic (> 21 days), size 5-50 cm2 SD-101 3% (n=16) Secondary Efficacy Endpoints Include: Time to target wound closure Change in Body Surface Area (BSA) of lesional skin 42/44 Patients entered extension study $400K FDA Grant for Extension Study 48 EB patients (age > 6 months)1 - 1:1:1 Randomization - Daily Topical Application 1. Assessments: 0, 14, 30, 60, 90 Days. 2. Initial Disease Severity: Mean target lesion size (cm2) 14.0 (range 5-39); mean lesional BSA: 19.4% (range 0.4-48%); mean wound age (days): 182 (range 21-1,639). EB types enrolled: Simplex (n=11), Dystrophic (n=29), and Junctional (n=8) Optional Extension (SD-004)

GRAPHIC

 


Phase 2b Results SD-101 for EB 32 SD-101 6% Demonstrated Higher Proportion of Complete Target Wound Closure *SD-101 6% vs placebo, unadjusted p=0.04 ITT Population (n=48) Evaluable Population1 (n=45) (p=0.04)* Proportion of Complete Target Wound Closure (%) Proportion of Complete Target Wound Closure (%) 1. Excluded from Evaluable population: 1 patient (due to lost to follow-up), 2 patients (did not have single identified and qualified target lesion). 1 additional patient lost to follow up after Month 1 visit and is excluded from target wound assessment at later time points N=17 N=15 N=16 N=17 N=15 N=16 N=17 N=12 N=16 N=17 N=11 N=16 Placebo SD-101 3% SD-101 6% 41% 41% 38% 44% 67% 82% Month 1 Month 2 (Pre-specified Primary Endpoint) (Phase 3 Primary Endpoint) 41% 41% 38% 44% 53% 60% Month 1 Month 2 (Pre-specified Primary Endpoint) (Phase 3 Primary Endpoint)

GRAPHIC

 


Phase 2b Extension (Study 004) Results SD-101 for EB 33 Results on Total Body Surface Area (BSA) Affected by Wounds and Lesions Mean Absolute Change to Month 12 (95% CI): -3.41% (-7.0, 0.2) BL n=42 M3 n=37 M6 n=33 M9 n=30 M12 n=28 Note: Mean and SEM on change from baseline are plotted. Study 004 Total BSA baseline values are: N=42 Baseline population: 11.3. N=28 population used for Month 12 comparison: 10.9 3 6 9 12 -5 -4 -3 -2 -1 0 1 2 3 Baseline Time, Months C h a n g e i n T o t a l B S A f r o m B a s e l i n e ( % )

GRAPHIC

 


PHASE 3 ESSENCE STUDY STATUS >50% of target enrollment achieved 100% conversion to extension study (SD-006) Top-line Phase 3 data anticipated 4Q16/1H17 EB Program Update - Phase 3 ESSENCE Study (SD-005) SD-101 for EB 34 Following Recent Meeting with FDA, Amicus has Elevated Time to Wound Closure From Secondary to Co-Primary Endpoint. We Believe This Change Improves the Overall Likelihood of Study Success while ESSENCE Study Remains Blinded.

GRAPHIC

 


Elevation of Time to Wound Closure as Co-primary Endpoint SD-101 for EB 35 FDA 2006 Guidance Document1 States Time to Wound Closure is an Acceptable Primary Efficacy Endpoint Median Time to Wound Closure (Days) Median Time to Wound Closure (Days) 91 Days 86 Days 40 Days ITT Population (n=48) Evaluable Population (n=45) Placebo SD-101 3% SD-101 6% 91 Days 86 Days 30 Days N=17 N=15 N=16 N=17 N=12 N=16 Time to Wound Closure Encouraging results in SD-101 Phase 2b study Measuring healing over time vs. one time point may further control for placebo response Results correlate with incidence of complete wound closure Statistical simulations indicate addition of time to wound closure increases probability of study success Median Time to Wound Closure in Phase 2b Study 1http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm071324.pdf

GRAPHIC

 


Phase 3 ESSENCE Study Design (SD-005) SD-101 for EB 36 Study Success Potentially Based on Achievement of One or Both Co-Primary Endpoints ~150 EB patients (age > 1 month) Baseline wound: Chronic (> 21 days), size >10 cm2 Placebo SD-101 6% Primary Endpoint: Target Wound Healing at Month 2 US and EU regulatory authorities agreed on primary endpoint Baseline wound: Chronic (> 21 days), size >10 cm2 Primary Endpoint: Target Wound Healing at Month 2 US and EU regulatory authorities agreed on primary endpoint Baseline wound: Chronic (> 21 days), size >10 cm2 Co-Primary Endpoints Complete closure of target wound (previously specified primary endpoint) Time to target wound closure (elevated from secondary to co-primary) Secondary Endpoints Include: Change in Body Surface Area (BSA) of lesions and blisters Patient-reported itching Patient-reported pain 3-Month, Double-Blind Treatment Period Open-Label SD-101 6% Optional Extension (SD-006) 100% Participation in Extension Study (August 1, 2016) Covariates include age of patient and size of wound at baseline Average Baseline Target Wound Size in Phase 3 Population: ~20 cm2 (August 1, 2016)

GRAPHIC

 


$1B+ Commercial Potential SD-101 for EB 37 KOL Feedback Supports Profound Unmet Medical Need and Broad Usage in All EB Types Diagnosed EB Patients by Geography Significant Unmet Medical Need Significant Unmet Clinical Need No approved treatments, opportunity for first-in-class Promising proof of concept in all EB types Strong Support Among Surveyed Stakeholders Physicians indicate usage in 100% patients Payers indicate support for broad reimbursement if approved Large Commercial Opportunity 30,000 – 40,000 diagnosed patients in major markets KOLs expect diagnosis rates to increase (U.S., EU3, Japan) U.S. 52% EU3 35% Japan 13%

GRAPHIC

 


Cyclin-Dependent Kinase-Like 5 (CDKL5) Deficiency Genetic mutations in CDKL5 gene result in deficient protein essential for normal brain development Persistent, spontaneous seizures starting in infancy Severe impairment in neurological development Most affected children cannot walk, talk or care for themselves May include scoliosis, visual impairment, sensory issues, and gastrointestinal complications >1,200 documented cases worldwide1 Patient identification rising significantly CDKL5 Deficiency Program 38 Rare, Devastating, Genetic Neurological Disease with No Approved Treatments 1. LouLouFoundation.org

GRAPHIC

 


Strategic Fit with Amicus Vision and Biologics Pipeline CDKL5 Deficiency Program 39 New CDKL5 Program Expands Biologics Pipeline and Fits with Our Vision to Build a Leading Global Biotechnology Company Focused on Rare and Devastating Diseases CDKL5 is a rare, devastating genetic neurological disease with no approved treatment Potential first-in-class CDKL5 protein replacement therapy expands biologics pipeline Partnering with CDKL5 community to raise awareness and advance toward treatment 1 Third party market research - Michael Jasulavic, Founder of MiaMed I am confident the Company’s advancement of this program will raise CDKL5 awareness and, most importantly, increase the potential for success in developing a CDKL5 protein replacement therapy.” - Ashley R. Winslow, PhD, Director of Neurogenetics of the Orphan Disease Center at University of Pennsylvania Today there is no approved treatment for people living with CDKL5 deficiency, and the number of patients diagnosed has been increasing rapidly ” -John F. Crowley, Chairman and CEO of Amicus This CDKL5 program is an important investment in our stated strategy to expand our biologics pipeline by integrating new, innovative technologies to develop first- and best-in-class therapies for patients who are in desperate need of new treatments.”

GRAPHIC

 


Financial Summary Strong Balance Sheet to Invest in Rare Disease Pipeline

GRAPHIC

 


Strong Balance Sheet Financial Summary 41 Financial Position June 30, 2016 Cash: $214.2M Debt $80.0M FY16 Net Cash Spend Guidance: $135-$155M (maintained) Cash Runway Into 2H17 Full Allotment Raised in ATM (average price per share: $6.67) $100M ($61.7M in 2Q; $39.3M in 3Q) Capitalization Shares Outstanding 134,408,526 Cash Position Provides Runway Under Current Operating Plan into mid-2017 Balance Sheet Strengthened with $130M in Equity and Debt Proceeds Since March 31 with Cash Runway into 2H17

GRAPHIC

 


Key Drivers of Value Conclusion 42 3 Novel Product Candidates Each with $500M to $1B+ Market Potential Galafold Precision Medicine (Small Molecule) EU Full Approval Launched in Germany (May 30, 2016) U.S. regulatory update anticipated 3Q16 Phase 3 Novel Topical Cream (SD-101) U.S. Breakthrough Therapy Designation Rolling NDA Phase 3 Data targeted in 4Q16/1H17 Novel ERT + Chaperone Treatment Paradigm Biologics Manufacturing Interim Data Anticipated in 4Q16 R&D Engine and Continued Business Development Activity Pompe Epidermolysis Bullosa (EB) Fabry

GRAPHIC

 


Thank You ©AMICUS THERAPEUTICS. CRANBURY, NJ. 2016

GRAPHIC

 

GRAPHIC 3 g165531mmi001.gif GRAPHIC begin 644 g165531mmi001.gif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η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�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�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